(PNNT) PennantPark Investment - Overview
Stock: Mezzanine Debt, Senior Loans, Equity Stakes
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 14.47% |
| Yield on Cost 5y | 30.57% |
| Yield CAGR 5y | 18.92% |
| Payout Consistency | 94.3% |
| Payout Ratio | 45.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 18.1% |
| Relative Tail Risk | -0.04% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.30 |
| Alpha | -17.11 |
| Character TTM | |
|---|---|
| Beta | 0.677 |
| Beta Downside | 0.727 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.15% |
| CAGR/Max DD | 0.71 |
Description: PNNT PennantPark Investment December 28, 2025
PennantPark Investment Corporation (NYSE: PNNT) is a Business Development Company (BDC) that operates as a private-equity-style fund, targeting direct and mezzanine capital placements in U.S. middle-market companies across a broad array of sectors, from real estate and hospitality to technology, healthcare, and energy.
The firm typically deploys $10 million-$100 million of capital across the capital structure-senior secured loans, subordinated debt, and equity-into companies with EBITDA of $10 million-$50 million and revenue of $50 million-$1 billion. Mezzanine and senior loan exposures usually range from $15 million-$50 million, while equity commitments can reach up to $250 million, often in non-control positions.
As of the latest filing, PNNT reported an asset base of roughly $1.1 billion and a dividend yield near 9%, reflecting the BDC’s reliance on high-yield debt in a low-interest-rate environment; however, rising Fed rates could pressure net interest margins and borrowing costs for portfolio companies. Historically, BDCs allocate about 70% of assets to debt instruments, a pattern that aligns with PennantPark’s emphasis on mezzanine and senior secured loans. A key driver for its portfolio performance is the health of the U.S. middle-market, which has shown a 3-4% annual revenue growth rate over the past three years, but remains sensitive to macro-economic tightening.
For a deeper, data-driven view of PNNT’s valuation and risk profile, you might find the analytics on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 32.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 29.44 > 1.0 |
| NWC/Revenue: -89.01% < 20% (prev -38.06%; Δ -50.95% < -1%) |
| CFO/TA 0.17 > 3% & CFO 229.8m > Net Income 32.7m |
| Net Debt (687.1m) to EBITDA (77.0m): 8.93 < 3 |
| Current Ratio: 0.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.3m) vs 12m ago -0.22% < -2% |
| Gross Margin: 62.48% > 18% (prev 0.69%; Δ 6180 % > 0.5%) |
| Asset Turnover: 7.36% > 50% (prev 10.35%; Δ -3.00% > 0%) |
| Interest Coverage Ratio: 0.00 > 6 (EBITDA TTM 77.0m / Interest Expense TTM 10.09b) |
Altman Z'' -1.29
| A: -0.07 (Total Current Assets 57.0m - Total Current Liabilities 146.7m) / Total Assets 1.35b |
| B: -0.20 (Retained Earnings -276.6m / Total Assets 1.35b) |
| C: 0.02 (EBIT TTM 28.7m / Avg Total Assets 1.37b) |
| D: -0.31 (Book Value of Equity -276.6m / Total Liabilities 885.6m) |
| Altman-Z'' Score: -1.29 = CCC |
What is the price of PNNT shares?
Over the past week, the price has changed by -2.20%, over one month by -3.04%, over three months by -7.21% and over the past year by -6.23%.
Is PNNT a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the PNNT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.2 | 6.2% |
| Analysts Target Price | 6.2 | 6.2% |
| ValueRay Target Price | 7.1 | 23.1% |
PNNT Fundamental Data Overview January 28, 2026
P/E Forward = 9.6246
P/S = 3.1587
P/B = 0.8332
P/EG = 0.279
Revenue TTM = 100.7m USD
EBIT TTM = 28.7m USD
EBITDA TTM = 77.0m USD
Long Term Debt = unknown (none)
Short Term Debt = 149.5m USD (from shortTermDebt, last fiscal year)
Debt = 738.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 687.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.07b USD (386.6m + Debt 738.9m - CCE 51.8m)
Interest Coverage Ratio = 0.00 (Ebit TTM 28.7m / Interest Expense TTM 10.09b)
EV/FCF = 4.67x (Enterprise Value 1.07b / FCF TTM 229.8m)
FCF Yield = 21.41% (FCF TTM 229.8m / Enterprise Value 1.07b)
FCF Margin = 228.1% (FCF TTM 229.8m / Revenue TTM 100.7m)
Net Margin = 32.48% (Net Income TTM 32.7m / Revenue TTM 100.7m)
Gross Margin = 62.48% ((Revenue TTM 100.7m - Cost of Revenue TTM 37.8m) / Revenue TTM)
Gross Margin QoQ = -3.51% (prev 68.89%)
Tobins Q-Ratio = 0.80 (Enterprise Value 1.07b / Total Assets 1.35b)
Interest Expense / Debt = 1362 % (Interest Expense 10.06b / Debt 738.9m)
Taxrate = 7.33% (2.59m / 35.3m)
NOPAT = 26.6m (EBIT 28.7m * (1 - 7.33%))
Current Ratio = 0.39 (Total Current Assets 57.0m / Total Current Liabilities 146.7m)
Debt / Equity = 1.59 (Debt 738.9m / totalStockholderEquity, last quarter 463.9m)
Debt / EBITDA = 8.93 (Net Debt 687.1m / EBITDA 77.0m)
Debt / FCF = 2.99 (Net Debt 687.1m / FCF TTM 229.8m)
Total Stockholder Equity = 481.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.39% (Net Income 32.7m / Total Assets 1.35b)
RoE = 6.79% (Net Income TTM 32.7m / Total Stockholder Equity 481.7m)
RoCE = 2.38% (EBIT 28.7m / Capital Employed (Total Assets 1.35b - Current Liab 146.7m))
RoIC = 2.27% (NOPAT 26.6m / Invested Capital 1.17b)
WACC = 2.89% (E(386.6m)/V(1.13b) * Re(8.41%) + (debt cost/tax rate unavailable))
Discount Rate = 8.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.05%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈229.8m ; Y1≈150.9m ; Y5≈68.8m
Fair Price DCF = 23.07 (EV 2.19b - Net Debt 687.1m = Equity 1.51b / Shares 65.3m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: -30.97 | EPS CAGR: -46.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: -27.92 | Revenue CAGR: -32.99% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.17 | Chg30d=+0.000 | Revisions Net=-2 | Analysts=8
EPS current Year (2026-09-30): EPS=0.66 | Chg30d=+0.015 | Revisions Net=-3 | Growth EPS=-6.6% | Growth Revenue=-8.6%
EPS next Year (2027-09-30): EPS=0.63 | Chg30d=+0.001 | Revisions Net=+1 | Growth EPS=-4.7% | Growth Revenue=-2.2%